

COPY

VPI/98-18 US

BICYCLIC DERIVATIVES

5

TECHNICAL FIELD OF THE INVENTION

The present invention relates to bicyclic derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention
10 also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.

BACKGROUND OF THE INVENTION

15 Neurological diseases are associated with the death of or injury to neuronal cells. Typical treatment of neurological diseases involves drugs capable of inhibiting neuronal cell death. A more recent approach involves the promotion of nerve regeneration by promoting
20 neuronal growth.

Neuronal growth, which is critical for the survival of neurons, is stimulated *in vitro* by nerve growth factors (NGF). For example, Glial Cell Line-Derived Neurotrophic Factor (GDNF) demonstrates
25 neurotrophic activity both, *in vivo* and *in vitro*, and is currently being investigated for the treatment of Parkinson's disease. Insulin and insulin-like growth factors have been shown to stimulate growth of neurites in rat pheochromocytoma PC12 cells and in cultured
30 sympathetic and sensory neurons [Recio-Pinto et al., J. Neurosci., 6, pp. 1211-1219 (1986)]. Insulin and insulin-like growth factors also stimulate the

regeneration of injured motor nerves *in vivo* and *in vitro* [Near et al., Proc. Natl. Acad. Sci., pp. 89, 11716-11720 (1992); and Edbladh et al., Brain Res., 641, pp. 76-82 (1994)]. Similarly, fibroblast growth factor (FGF) stimulates neural proliferation [D. Gospodarowicz et al., Cell Differ., 19, p. 1 (1986)] and growth [M. A. Walter et al., Lymphokine Cytokine Res., 12, p. 135 (1993)].

There are, however, several disadvantages associated with the use of nerve growth factors for treating neurological diseases. They do not readily cross the blood-brain barrier. They are unstable in plasma and they have poor drug delivery properties.

Recently, small molecules have been shown to stimulate neurite outgrowth *in vivo*. In individuals suffering from a neurological disease, this stimulation of neuronal growth protects neurons from further degeneration, and accelerates the regeneration of nerve cells. For example, estrogen has been shown to promote the growth of axons and dendrites, which are neurites sent out by nerve cells to communicate with each other in a developing or injured adult brain [(C. Dominique Toran-Allerand et al., J. Steroid Biochem. Mol. Biol., 56, pp. 169-78 (1996); and B. S. McEwen et al., Brain Res. Dev. Brain. Res., 87, pp. 91-95 (1995)]. The progress of Alzheimer's disease is slowed in women who take estrogen. Estrogen is hypothesized to complement NGF and other neurotrophins and thereby help neurons differentiate and survive.

Other target sites for the treatment of neurodegenerative disease are the immunophilin class of proteins. Immunophilins are a family of soluble proteins that mediate the actions of immunosuppressant drugs such

as cyclosporin A, FK506 and rapamycin. Of particular interest is the 12 kDa immunophilin, FK-506 binding protein (FKBP12). FKBP12 binds FK-506 and rapamycin, leading to an inhibition of T-cell activation and proliferation. Interestingly, the mechanism of action of FK-506 and rapamycin are different. For a review, see, S. H. Solomon et al., Nature Med., 1, pp. 32-37 (1995). It has been reported that compounds with an affinity for FKBP12 that inhibit that protein's rotomase activity possess nerve growth stimulatory activity. [Lyons et al., Proc. Natl. Acad. Sci. USA, 91, pp. 3191-3195 (1994)]. Many of these such compounds also have immunosuppressive activity.

FK506 (Tacrolimus) has been demonstrated to act synergistically with NGF in stimulating neurite outgrowth in PC12 cells as well as sensory ganglia [Lyons et al. (1994)]. This compound has also been shown to be neuroprotective in focal cerebral ischemia [J. Sharkey and S. P. Butcher, Nature, 371, pp. 336-339 (1994)] and to increase the rate of axonal regeneration in injured sciatic nerve [B. Gold et al., J. Neurosci., 15, pp. 7509-16 (1995)].

The use of immunosuppressive compounds, however, has drawbacks in that prolonged treatment with these compounds can cause nephrotoxicity [Kopp et al., J. Am. Soc. Nephrol., 1, p. 162 (1991)], neurological deficits [P.C. DeGroen et al., N. Eng. J. Med., 317, p. 861 (1987)] and vascular hypertension [Kahan et al., N. Eng. J. Med., 321, p. 1725 (1989)].

More recently, sub-classes of FKBP binding compounds which inhibit rotomase activity, but which purportedly lack immunosuppressive function have been

disclosed for use in stimulating nerve growth [see,
United States patent 5,614,547; WO 96/40633; WO 96/40140;
WO 97/16190; J. P. Steiner et al., Proc. Natl. Acad. Sci.
USA, 94, pp. 2019-23 (1997); and G. S. Hamilton et al.,
5 Bioorg. Med. Chem. Lett., 7, pp. 1785-90 (1997)].


Stimulation of neural axons in nerve cells by
piperidine derivatives is described in WO 96/41609.
Clinical use of the piperidine and pyrrolidine
derivatives known so far for stimulating axonal growth
10 has not been promising, as the compounds are unstable in
plasma and do not pass the blood-brain barrier in
adequate amounts.

Though a wide variety of neurological
degenerative diseases may be treated by promoting repair
15 of neuronal damage, there are relatively few agents known
to possess these properties. Thus, there remains a need
for new compounds and compositions that have the ability
to either prevent or treat neuronal damage associated
with neuropathologic diseases.


20

SUMMARY OF THE INVENTION

The present invention provides compounds having
formula (I) or formula (II):



(I)



(II)

25

and pharmaceutically acceptable derivatives thereof,
wherein:

X is O, S, $C(R^1)_2$ or NR^1 ;

y is 1 or 2;

5 A, B and R^1 are independently E, (C_1-C_{10}) -straight or
branched alkyl, (C_2-C_{10}) -straight or branched alkenyl or
alkynyl, or (C_5-C_7) -cycloalkyl or cycloalkenyl; wherein 1
or 2 hydrogen atoms in said alkyl, alkenyl or alkynyl are
optionally and independently replaced with E, (C_5-C_7) -
10 cycloalkyl or cycloalkenyl; and wherein 1 to 2 methylene
($-CH_2-$) groups in said alkyl, alkenyl, or alkynyl groups
are optionally and independently replaced by $-O-$, $-S-$,
 $-S(O)-$, $-S(O)_2-$, $=N-$, $-N=$ or $-N(R^3)-$;

or B and R^1 are independently hydrogen;

15 wherein R^3 is selected from hydrogen, (C_1-C_4) -
straight or branched alkyl, (C_3-C_4) -straight or branched
alkenyl or alkynyl, or (C_1-C_4) bridging alkyl, wherein
said bridge is formed between the nitrogen atom to which
said R^3 is bound and any carbon atom of said alkyl,
20 alkenyl or alkynyl to form a ring, and wherein said ring
is optionally benzofused;

wherein E is a saturated, partially saturated or
unsaturated, or aromatic monocyclic or bicyclic ring
system, wherein each ring comprises 5 to 7 ring atoms
25 independently selected from C, N, O or S; and wherein no
more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are
optionally and independently replaced with halogen,
hydroxyl, hydroxymethyl, nitro, SO_3H , trifluoromethyl,
30 trifluoromethoxy, (C_1-C_6) -straight or branched alkyl,
 (C_2-C_6) -straight or branched alkenyl, $O-[(C_1-C_6)$ -straight
or branched alkyl], $O-[(C_3-C_6)$ -straight or branched

alkenyl], $(\text{CH}_2)_n\text{-N}(\text{R}^4)(\text{R}^5)$, $(\text{CH}_2)_n\text{-NH}(\text{R}^4)\text{-(CH}_2)_n\text{-Z}$,
 $(\text{CH}_2)_n\text{-N}(\text{R}^4\text{-(CH}_2)_n\text{-Z})(\text{R}^5\text{-(CH}_2)_n\text{-Z})$, $(\text{CH}_2)_n\text{-Z}$, $\text{O-(CH}_2)_n\text{-Z}$,
 $(\text{CH}_2)_n\text{-O-Z}$, $\text{S-(CH}_2)_n\text{-Z}$, CH=CH-Z , 1,2-methylenedioxy,
 C(O)OH , $\text{C(O)O-[(C}_1\text{-C}_6\text{)-straight or branched alkyl]}$,
5 $\text{C(O)O-(CH}_2)_n\text{-Z}$ or $\text{C(O)-N}(\text{R}^4)(\text{R}^5)$;

wherein each of R^4 and R^5 are independently
hydrogen, $(\text{C}_1\text{-C}_6)$ -straight or branched alkyl, $(\text{C}_3\text{-C}_5)$ -
straight or branched alkenyl, or wherein R^4 and R^5 , when
bound to the same nitrogen atom, are taken together with
10 the nitrogen atom to form a 5 or 6 membered ring, wherein
said ring optionally contains 1 to 3 additional
heteroatoms independently selected from N, O or S;
wherein said alkyl, alkenyl or alkynyl groups in R_4 and R_5
are optionally substituted with Z.

15 each n is independently 0 to 4;

each Z is independently selected from a saturated,
partially saturated or unsaturated, monocyclic or
bicyclic ring system, wherein each ring comprises 5 to 7
ring atoms independently selected from C, N, O or S; and
20 wherein no more than 4 ring atoms are selected from N, O
or S;

wherein 1 to 4 hydrogen atoms in Z are optionally
and independently replaced with halo, hydroxy, nitro,
cyano, C(O)OH , $(\text{C}_1\text{-C}_3)$ -straight or branched alkyl,
25 $\text{O-(C}_1\text{-C}_3)$ -straight or branched alkyl,
 $\text{C(O)O-[(C}_1\text{-C}_3)$ -straight or branched alkyl], amino,
 $\text{NH[(C}_1\text{-C}_3)$ -straight or branched alkyl], or
 $\text{N-[(C}_1\text{-C}_3)$ -straight or branched alkyl]₂.

wherein 1 to 4 hydrogen atoms in the bicyclic ring
30 of formula (I) or formula (II) are optionally and
independently replaced with Q;

wherein Q is selected from E, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is optionally and independently
5 replaced with E;


wherein Q is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl, O-(CH₂)_n-Z, NO₂, CO₂H, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵, NR⁴R⁵ and (CH₂)_n-Z; and

10 the bicyclic rings of formula (I) and formula (II) are optionally be benzo fused.


In another embodiment, the invention provides compositions comprising the compounds of formula (I). These compositions may be utilized in methods treating
15 various neurological diseases which are influenced by neuronal regeneration and axon growth or for stimulating neuronal regeneration in an ex vivo nerve cell. Examples of such diseases include peripheral nerve destruction due to physical injury or diseases such as diabetes; physical
20 injuries to the central nervous system (e.g., brain or spinal cord); stroke; neurological disturbances due to nerve degeneration, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds having formula (I) or formula (II):



(I)



(II)

and pharmaceutically acceptable derivatives thereof,

5 wherein:

X is O, S, $C(R^1)_2$ or NR^1 ;

y is 1 or 2;

A, B and R^1 are independently E, (C_1-C_{10}) -straight or
 branched alkyl, (C_2-C_{10}) -straight or branched alkenyl or
 10 alkynyl, or (C_5-C_7) -cycloalkyl or cycloalkenyl; wherein 1
 or 2 hydrogen atoms in said alkyl, alkenyl or alkynyl are
 optionally and independently replaced with E, (C_5-C_7) -
 cycloalkyl or cycloalkenyl; and wherein 1 to 2 methylene
 $(-CH_2-)$ groups in said alkyl, alkenyl, or alkynyl groups
 15 are optionally and independently replaced by $-O-$, $-S-$,
 $-S(O)-$, $-S(O)_2-$, $=N-$, $-N=$ or $-N(R^3)-$;

or B and R^1 are independently hydrogen;

wherein R^3 is selected from hydrogen, (C_1-C_4) -
 straight or branched alkyl, (C_3-C_4) -straight or branched
 20 alkenyl or alkynyl, or (C_1-C_4) bridging alkyl, wherein
 said bridge is formed between the nitrogen atom to which
 said R^3 is bound and any carbon atom of said alkyl,
 alkenyl or alkynyl to form a ring, and wherein said ring
 is optionally benzofused;

25 wherein E is a saturated, partially saturated or
 unsaturated, or aromatic monocyclic or bicyclic ring
 system, wherein each ring comprises 5 to 7 ring atoms

independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen,
5 hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl], O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z,
10 (CH₂)_n-N(R⁴-(CH₂)_n-Z)(R⁵-(CH₂)_n-Z), (CH₂)_n-Z, O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C₁-C₆)-straight or branched alkyl], C(O)O-(CH₂)_n-Z or C(O)-N(R⁴)(R⁵);

wherein each of R⁴ and R⁵ are independently
15 hydrogen, (C₁-C₆)-straight or branched alkyl, (C₃-C₅)-straight or branched alkenyl, or wherein R⁴ and R⁵, when bound to the same nitrogen atom, are taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional
20 heteroatoms independently selected from N, O or S; wherein said alkyl, alkenyl or alkynyl groups in R₄ and R₅ are optionally substituted with Z.

each n is independently 0 to 4;

each Z is independently selected from a saturated,
25 partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

30 wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C₁-C₃)-straight or branched alkyl,

O-(C₁-C₃)-straight or branched alkyl,
C(O)O-[(C₁-C₃)-straight or branched alkyl], amino,
NH[(C₁-C₃)-straight or branched alkyl], or
N-[(C₁-C₃)-straight or branched alkyl]₂.

5 wherein 1 to 4 hydrogen atoms in the bicyclic ring
of formula (I) or formula (II) are optionally and
independently replaced with Q;

 wherein Q is selected from E, (C₁-C₆)-straight or
branched alkyl, (C₂-C₆)-straight or branched alkenyl or
10 alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl,
alkenyl or alkynyl is optionally and independently
replaced with E;

 wherein Q is optionally substituted with up to 3
substituents selected from halogen, OH, O-(C₁-C₆)-alkyl,
15 O-(CH₂)_n-Z, NO₂, CO₂H, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵,
NR⁴R⁵ and (CH₂)_n-Z; and

 the bicyclic rings of formula (I) and formula (II)
are optionally be benzo fused.

 According to a preferred embodiment, each of A
20 and B in formula (I) is (C₁-C₁₀) straight or branched
alkyl, wherein 1-2 hydrogen atoms in said alkyl are
optionally substituted with E.

 In another preferred embodiment, B is hydrogen.

 According to a more preferred embodiment, each
25 of A and B in formula (I) is -CH₂-CH₂-E or -CH₂-CH₂-CH₂-E.

 According to another preferred embodiment, E in
formula (I) is a monocyclic or bicyclic aromatic ring
system, wherein said ring comprises 5-7 ring atoms
independently selected from C, N, O or S, and wherein 1
30 to 4 ring atoms are independently selected from N, O or
S.


According to a more preferred embodiment, E is selected from the group consisting of phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, 5 imidazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isothiazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, benzo[b]furanyl, benzo[b]thiophenyl, purinyl, cinnolinyl, phthalazinyl, isoxazolyl, triazolyl, oxadiazolyl, 10 pyrimidinyl, pyrazinyl, indolinyl, indoliziny, isoindolyl, benzimidazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phnazinyl, phenothiazinyl, phenoxazinyl and 15 benzothiazolyl, wherein E is optionally substituted as described above.

More preferred embodiments of E include phenyl, furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl, 20 oxadiazolyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and benzothiazolyl, wherein E is optionally substituted as described above.


The compounds of formula (I) may be 25 stereoisomers, geometric isomers or stable tautomers. The invention envisions all possible isomers, such as E and Z isomers, S and R enantiomers, diastereoisomers, racemates, and mixtures of those. It is preferred that the substituent in the 2 position have the S 30 configuration.

The compounds of the present invention may be readily prepared using known synthetic methods. For

example, compounds of formula (I) and formula (II) may be prepared as shown below in Scheme I and Scheme II:



Scheme I



Scheme II

wherein A, B, X and y are as defined above in formula (I). Compounds of formula (A) are known in the prior art. See, Bulacinsli, Polish J. Chem., 52, p. 2181 (1978); Grob et al., Helv. Chim. Acta, 37, p. 2119 and 2122 (1954); Gassman et al., J. Org. Chem. 32, p. 480 (1967); Orlek et al., J. Med. Chem. 34, p. 2726-2735 (1991); Jenkins et al., J. Med. Chem. 35, p. 2392-2406 (1992); Saunders et al., J. Med. Chem. 33, p. 1128-1138 (1990); MacLeod et al., J. Chem. Soc., Chem. Comm., p. 100-102 (1990); MacLeod et al., Tetrahedron, 33, p. 4217-4220 (1992); MacLeod et al., J. Med. Chem., p. 2052-2069

(1990); Snow et al., Tetrahedron, 30 p. 5795-5798 (1989);
Leslie et al., J. Med. Chem. 35, p. 295-305 (1992);
Pouwels and Veldstra, Recl. Trav. Chim. Pays-Bas, 74, p.
795, 803 (1955); Grob et al., Helv. Chim. Acta, 40, p.
2170, 2180 (1957); Michline et al., J. Gen. Chem. USSR
5 (Engl. Transl.) 33, p. 3791 (1963); Snow et al., J. Chem.
Soc., Perkin Trans. 1, p. 409-420 (1991); Grethe et al.,
J. Amer. Chem. Soc., 100, p. 581, 584, 588 (1978);
Saunders et al., J. Chem. Soc., Chem. Comm., p. 1618
10 (1988). In addition to the above synthetic Scheme, one
of skill in the art would be well aware of other
synthetic routes to the compounds of the present
invention.

According to another embodiment, this invention
15 provides compositions comprising a compound of formula
(I) and a carrier.

Carriers that may be used in these compositions
include, but are not limited to, ion exchangers, alumina,
aluminum stearate, lecithin, serum proteins, such as
20 human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, potassium sorbate,
partial glyceride mixtures of saturated vegetable fatty
acids, water, salts or electrolytes, such as protamine
sulfate, disodium hydrogen phosphate, potassium hydrogen
25 phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-
based substances, polyethylene glycol, sodium carboxy
methylcellulose, polyacrylates, waxes, polyethylene-
polyoxypropylene-block polymers, polyethylene glycol and
30 wool fat.

In another embodiment, the composition of the present invention is comprised of a compound of formula (I), a carrier, and a neurotrophic factor.

The term "neurotrophic factor," as used herein,
5 refers to compounds which are capable of stimulating growth or proliferation of nervous tissue. Numerous neurotrophic factors have been identified in the art and any of those factors may be utilized in the compositions of this invention. These neurotrophic factors include,
10 but are not limited to, nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth factors (PDGF),
15 brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5). The most preferred neurotrophic factor in the compositions of this invention
20 is NGF.

As used herein, the described compounds used in the compositions and methods of this invention, are defined to include derivatives thereof. A "derivative" denotes any salt, ester, or salt of such ester, of a
25 compound of this invention or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to promote repair or prevent damage of neurons
30 from disease or physical trauma.

If salts of the described compounds are used, those salts are preferably derived from inorganic or

organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, 5 ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, lactate, maleate, hydroxyethanesulfonate, 2-naphthalenesulfonate, 2-10 methanesulfonate, pectinate, persulfate, nicotinate, oxalate, pamoate, propionate, succinate, propionate, picrate, pivalate, and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth salts, such as 15 such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-20 containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, 25 long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

30 The described compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such

modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase
5 solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally
10 or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
15 Preferably, the compositions are administered orally, intraperitoneally or intravenously.

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to
20 techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution
25 in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any
30 bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation.

of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain
5 alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.

The compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous
10 suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include
15 lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

20 Alternatively, the compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature
25 but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The compositions of this invention may also be administered topically, especially when the target of
30 treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical

formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
5 Topically-transdermal patches may also be used.

For topical applications, the compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the
15 compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl
20 alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or
25 without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the compositions may be formulated in an ointment such as petrolatum.

The compositions of this invention may also be administered by nasal aerosol or inhalation. Such
30 compositions are prepared according to techniques well-known in the art of formulation and may be prepared as solutions in saline, employing benzyl alcohol or other

suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

The amount of both a described compound and the optional neurotrophic factor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the described compound can be administered. If a neurotrophic factor is present in the composition, then a dosage of between 0.01 µg - 100 mg/kg body weight/day of the neurotrophic factor can be administered to a patient receiving these compositions.

It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular described compound and neurotrophic factor in the composition.

According to another embodiment, this invention provides methods for promoting repair or preventing neuronal damage *in vivo* or in an *ex vivo* nerve cell. Such methods comprise the step of treating nerve cells with any of the compounds described above. Preferably, this method promotes repair or prevents neuronal damage

in a patient, and the compound is formulated into a composition additionally comprising a carrier. The amount of the compound utilized in these methods is between about 0.01 and 100 mg/kg body weight/day.

5 According to an alternate embodiment, the method of promoting repair or preventing neuronal damage comprises the additional step of treating nerve cells with a neurotrophic factor, such as those contained in the compositions of this invention. This embodiment
10 includes administering the compound and the neurotrophic agent in a single dosage form or in separate, multiple dosage forms. If separate dosage forms are utilized, they may be administered concurrently, consecutively or within less than about 5 hours of one another.

15 Preferably, the methods of this invention are used to stimulate axonal growth in nerve cells. The compounds are, therefore, suitable for treating or preventing neuronal damage caused by a wide variety of diseases or physical traumas. These include, but are not
20 limited to, Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, Tourette's syndrome, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, spinal cord injuries and facial
25 nerve crush.

 In a particularly preferred embodiment of the invention, the method is used to treat a patient suffering from trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular
30 dystrophy, muscle injury, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured, or prolapsed intervertebrae disk syndrome's,

cervical spondylosis, plexus disorders, thoracic outlet
destruction syndromes, peripheral neuropathies, such as
those caused by lead, dapson, ticks, or porphyria, other
peripheral myelin disorders, Alzheimer's disease,
5 Guillain-Barre syndrome, Parkinson's disease and other
Parkinsonian disorders, ALS, Tourette's syndrome,
multiple sclerosis, other central myelin disorders,
stroke and ischemia associated with stroke, neural
paropathy, other neural degenerative diseases, motor
10 neuron diseases, sciatic crush, neuropathy associated
with diabetes, spinal cord injuries, facial nerve crush
and other trauma, chemotherapy- and other medication-
induced neuropathies, and Huntington's disease.

More preferably, the compositions of the
15 present invention are used for treating Parkinson's
disease, amyotrophic lateral sclerosis, Alzheimer's
disease, stroke, neuralgias, muscular atrophies, and
Guillain-Barré syndrome.

For use of the compounds according to the
20 invention as medications, they are administered in the
form of a preparation containing not only the active
ingredient but also carriers, auxiliary substances,
and/or additives suitable for enteric or parenteral
administration. Administration can be oral or sublingual
25 as a solid in the form of capsules or tablets, as a
liquid in the form of solutions, suspensions, elixirs,
aerosols or emulsions, or rectal in the form of
suppositories, or in the form of solutions for injection
which can be given subcutaneously, intramuscularly, or
30 intravenously, or which can be given topically or
intrathecally. Auxiliary substances for the desired
medicinal formulation include the inert organic and

inorganic carriers known to those skilled in the art, such as water, gelatin, gum arabic, lactose, starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The medicinal formulations may also contain
5 preservatives, stabilizers, wetting agents, emulsifiers, or salts to change the osmotic pressure or as buffers.

Solutions or suspensions for injection are suitable for parenteral administration, and especially aqueous solutions of the active compounds in polyhydroxy-
10 ethoxylated castor oil.

Surface-active auxiliary substances such as salts of gallic acid, animal or vegetable phospholipids, or mixtures of them, and liposomes or their components, can be used as carrier systems.

15 The neurotrophic effect of the compounds of formula (I) of the present invention and their physiologically acceptable salts can be determined by the methods of W. E. Lyons et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 3191-3195 (1994) and W. E. Lyons et
20 al., Proc. Natl. Acad. Sci. USA, Vol. 91, pages 3191-3195 (1994).

In order that this invention may be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are
25 not to be construed as limiting the scope of the invention in any way.